This study is testing the safety and how the body processes a new drug called exidavnemab in people with mild to moderate Parkinson's disease or multiple system atrophy. About 38 participants will receive either the drug or a placebo to see how well it is tolerated. The main goal…
Phase: PHASE2 • Sponsor: BioArctic AB • Aim: Disease control
Last updated Mar 20, 2026 14:48 UTC